A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19
Phase 2
Withdrawn
- Conditions
- COVID-19
- Interventions
- Drug: PlaceboDrug: BRII-196 and BRII-198
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Brii Biosciences, Inc.
- Registration Number
- NCT04770467
- Locations
- 🇨🇳
Investigative Site 1, Hong Kong, China
© Copyright 2025. All Rights Reserved by MedPath